NGOs protest Novartis' Glivec patent quest in India
February 23, 2012 in Medications
Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.
The NGOs said that Novartis' action threatens access to generic drugs in poor countries.
The Berne Declaration, Act Up and Oxfam asked Novartis annual management and shareholders meeting in Basel "to abandon its legal action in India for obtaining a Glivec patent."
"We are asking Novartis once and for all to stop this legal battle in India that is a direct attack on the pharmacy of the developing world," Unni Karunakara, MSF's international president said in a letter to Novartis.
"We will not stand by silently and watch our source of affordable medicines dry up in the future -- we rely on these drugs to do our work in more than 60 countries today."
Forty activists gathered outside the Novartis building, erecting a booth and hoisting banners denouncing Novartis' position.
Glivec generated sales of $4.7 billion (3.5 billion euros) in 2011 and is used in the treatment of chronic myeloid leukemia (blood and bone marrow cancer) as well as against gastrointestinal cancer.
In applying for a patent, "access to cheap medicines would be threatened for the poor in developing countries and emerging economies and India is one of the main suppliers of generic drugs in the world," said Swiss NGO Berne Declaration in a statement.
According to Oxfam, "the price of Novartis' Glivec is 10 times higher than the cost of generic equivalents."
Novartis filed in 2006 a patent application for Glivec in India.
Indian courts rejected the request this year, saying the drug was a new formulation of an existing product.
The Swiss company has appealed to the Supreme Court of India, which has pushed from February to mid-March its hearing on the case, Patrick Durisch, an activist from the Berne Declaration told AFP.
Novartis, contacted by AFP, was not immediately available for comment.
(c) 2012 AFP
-
India patent case threatens cheap drug supply: MSF
Sep 05, 2011 |
not rated yet |
0
-
Novartis fights patent rejection in Indian court
Sep 06, 2011 |
not rated yet |
0
-
Novartis announces 2,000 job losses, profits up
Oct 25, 2011 |
not rated yet |
0
-
Novartis: Ovarian cancer drug disappoints in trial
May 27, 2010 |
not rated yet |
0
-
Swiss pharma giant Novartis recalls drugs in US
Jan 08, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
Pollen count apps for smartphones are nothing to sneeze at
Kate O'Reilly's spring allergy survival kit includes the usual stuff - nasal sprays, allergy pills and a box of tissues. This season, she's added a new weapon to her line of defense: an app on her smartphone.